Galeano, A. | Search bioRxiv

bioRxiv2026

Stereochemistry-Aware Drug-Target Affinity Prediction

Drug-target affinity (DTA) prediction is a key task in drug discovery, enabling the estimation of the interaction strength between candidate compounds and biological targets. However, current models rely on connectivity-based molecular representations and do not explicitly account for the spatial organization, also known as stereochemistry. This limitation becomes evident when considering chirality, where a drug can exist as enantiomers, i.e., molecules that share the same atoms and bonds but differ in their three-dimensional arrangement. Despite their chemical similarity, they can interact differently with the same target, leading to variations in binding affinity and biological activity. In this paper, we propose a stereochemistry-aware DTA prediction framework that incorporates this information into molecular representations. Drug representations are learned from chemical structure using a directed-bond message passing graph neural network that captures enantiomers configurations, while protein targets are represented through sequence-based embeddings. Experiments on the Davis dataset demonstrate that our model can improve affinity prediction. Importantly, a case study on a manually curated dataset of enantiomers with different biological action shows that the model is able to distinguish the affinities in the two forms consistent with their experimentally observed biological activity. These findings support the relevance of stereochemistry-aware molecular representation for more accurate and chemically faithful DTA prediction.

bioinformatics↗

bioRxiv2026

Learning Chirality-Aware Representations to Predict Drug Side Effect Frequencies

Ab initio prediction of side effect frequencies is important for assessing the risk-benefit profile of drugs and for identifying potential adverse effects early in development. A key challenge is chirality: many drugs exist as enantiomers, pairs of molecules with the same atoms and bond connectivity but different three-dimensional arrangements. Although chemically similar, enantiomers can interact differently with biological targets and therefore exhibit distinct efficacy and adverse-effect profiles. Here we introduce F2S (Features to Signatures), a method to predict the frequencies of drug side effects while explicitly accounting for chirality. Drug representations are learned directly from chemical structure using a directed-bond message-passing graph neural network that captures stereochemical configurations. Side effect representations are derived from curated textual descriptions encoded with a frozen PubMedBERT model. Side effect frequencies are predicted from the dot product between drug and side effect signatures together with biases for drugs and side effects. We evaluated F2S extensively across multiple settings, including cold-start and warm-start prediction, prospective evaluation, and scenarios controlling for chemical similarity between training and test drugs. Across these evaluations, F2S achieves performance comparable to state-of-the-art methods for general side-effect frequency prediction while producing fewer false positives and substantially improves the prediction of frequency differences between enantiomer pairs. Finally, F2S learns compact 10-dimensional signatures that support interpretability: drug signatures reflect therapeutic class and shared targets, side-effect signatures capture phenotype similarity, and the learned bias terms correlate with the popularity of drugs and side effects.

bioinformatics↗